Form 4: Johnson & Johnson Sells CVRx Shares

Johnson & Johnson, through its subsidiary, disposed of 6,337 shares of CVRx, Inc. common stock at a weighted average price of $10.03 per share.

Summary

• Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc., reported the sale of 6,337 shares of CVRx, Inc. common stock.
• The transaction occurred on November 26, 2025, at a weighted average price of $10.03 per share.
• The shares were sold in multiple transactions with prices ranging from $10.00 to $10.23.
• Following this transaction, Johnson & Johnson indirectly beneficially owns 4,040,861 shares of CVRx, Inc.
• The sale was made pursuant to a Rule 10b5-1(c) trading plan.

Sentiment

Score: 4

Explanation: The sale of shares by a significant institutional investor and 10% owner, Johnson & Johnson, is generally viewed as a negative signal, even if the amount is relatively small compared to their total holding. The transaction being part of a 10b5-1 plan mitigates some of the immediate negative interpretation but still represents a reduction in exposure.

Negatives

• Johnson & Johnson, a 10% owner and director, reduced its indirect beneficial ownership in CVRx, Inc. by selling 6,337 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the sale by a significant institutional investor as a lack of confidence or a strategic portfolio adjustment, potentially leading to negative sentiment or downward pressure on the stock price.

Key Dates

Recommendation

The sale of shares by Johnson & Johnson, a 10% owner and director, indicates a reduction in their stake in CVRx, Inc. While the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled, the act of divesting shares by a significant institutional investor can be interpreted as a negative signal regarding the company's near-term prospects or as a strategic portfolio reallocation away from CVRx. This action, even for a relatively small number of shares compared to their total holding, does not inspire confidence and suggests a 'sell' recommendation for investors considering the implications of such insider activity.

Keywords

CVRx Inc., CVRX, Johnson & Johnson, JJDC, Insider Sale, Form 4, Stock Transaction, Beneficial Ownership, Medical Devices